Back to Awarded Treatment Trials
Awarded Trial: 05T-705
Grant ID
05T-705
Illness
Schizophrenia
Primary Drug/Intervention
Rasagiline
Primary Dosage
2 mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Buchanan
Sample Size
60
Duration of Study Period for Each Subject
16 weeks
Outcome Measurements
Brief Psychiatric Rating Scale, Scale for the Assessment of Negative Symptoms, Calgary Depression Scale, Clinical Global Impression Scale, Schedule for the Deficit Syndrome, Simpson-Angus Extrapyramidal Symptom Rating Scale, Barnes Akathisia Scale
Results
Rasagiline 3 mg./day, an MAO-B inhibitor, was used as an adjuct for 60 patients with schizophrenia or schizoaffective disorder randomized to drug or placebo for 12 weeks. There was a trend toward greater improvement on the SANS for rasagiline (p=0.11) but it did not achieve significance. Rasagiline had no effect on cognitive symptoms.
Publication
Being submitted.
Link
N/A
PI Name
Robert Buchanan
Degree
MD
Center
Maryland Psychiatric Research Center
Institution
University of Maryland School of Medicine
Address
P.O. Box 21247
City or Town
Baltimore
State or Province
MD
Zip or Postal Code
21228
Country
USA
Email Address
rwbuchanan@mprc.umaryland.edu